Thanigaivelan Kanagasabai
Overview
Explore the profile of Thanigaivelan Kanagasabai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Celada S, Li G, Celada L, Kanagasabai T, Lu W, Brown L, et al.
Sci Signal
. 2024 Dec;
17(867):eadk4122.
PMID: 39689183
Resistance to androgen receptor (AR)-targeted therapies for prostate cancer (PCa) is characteristic of an aggressive subtype called castration-resistant prostate cancer (CRPC) and is often associated with tumor relapse. Both relapse...
2.
Dunbar Z, Gonzalez-Ochoa S, Kanagasabai T, Ivanova A, Shanker A
J Innate Immun
. 2024 Nov;
16(1):573-594.
PMID: 39561728
Introduction: Natural killer (NK) cells are innate lymphoid cells capable of directly killing target cells while modulating immune effector responses. Despite their multifunctional capacities, a limited understanding of their plasticity...
3.
Biocatalytic Potential of Pseudomonas Species in the Degradation of Polycyclic Aromatic Hydrocarbons
Sivasamy S, Rajangam S, Kanagasabai T, Bisht D, Prabhakaran R, Dhandayuthapani S
J Basic Microbiol
. 2024 Oct;
65(2):e2400448.
PMID: 39468883
Polycyclic aromatic hydrocarbons (PAHs), one of the major environmental pollutants, produced from incomplete combustion of materials like coal, oil, gas, wood, and charbroiled meat, that contaminate the air, soil, and...
4.
Chidambaram A, Prabhakaran R, Sivasamy S, Kanagasabai T, Thekkumalai M, Singh A, et al.
Technol Cancer Res Treat
. 2024 Jul;
23:15330338241261836.
PMID: 39043043
Male breast cancer (MBC), one of the rare types of cancer among men where the global incidence rate is 1.8% of all breast cancers cases with a yearly increase in...
5.
Farris T, Gonzalez-Ochoa S, Mohammed M, Rajakaruna H, Tonello J, Kanagasabai T, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000512
Brain pathological changes impair cognition early in disease etiology. There is an urgent need to understand aging-linked mechanisms of early memory loss to develop therapeutic strategies and prevent the development...
6.
Kanagasabai T, Hawaz M, Ellis K, Fah O, Mikhaeil H, Nguyen P, et al.
Dent Res Oral Health
. 2024 Jul;
7(2):58-65.
PMID: 38957610
Background: Topoisomerase IIα (TOP2A), is an enzyme involved in DNA replication, transcription, recombination, and chromatin remodeling and is found in a variety of cancers. However, the role of TOP2A regulation...
7.
Brown L, Kanagasabai T, Li G, Celada S, Rumph J, Adunyah S, et al.
Prostate
. 2024 Apr;
84(9):877-887.
PMID: 38605532
Background: Prostate cancer (PCa) is the second-leading cause of cancer mortalities in the United States and is the most commonly diagnosed malignancy in men. While androgen deprivation therapy (ADT) is...
8.
Kanagasabai T, Dunbar Z, Ochoa S, Farris T, Dhandayuthapani S, Wijeratne E, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339421
Background: Defects in apoptosis regulation are one of the classical features of cancer cells, often associated with more aggressiveness and failure to therapeutic options. We investigated the combinatorial antitumor effects...
9.
Celada S, Li G, Celada L, Lu W, Kanagasabai T, Feng W, et al.
Mol Oncol
. 2023 Jul;
17(10):2126-2146.
PMID: 37491794
Changes in FOXA1 (forkhead box protein A1) protein levels are well associated with prostate cancer (PCa) progression. Unfortunately, direct targeting of FOXA1 in progressive PCa remains challenging due to variations...
10.
Evans J, Suman S, Goruganthu M, Tchekneva E, Guan S, Arasada R, et al.
J Natl Cancer Inst
. 2023 May;
115(11):1404-1419.
PMID: 37195421
Background: We investigated the role of A2B-adenosine receptor in regulating immunosuppressive metabolic stress in the tumor microenvironment. Novel A2B-adenosine receptor antagonist PBF-1129 was tested for antitumor activity in mice and...